Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05751720

Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue

Effect on Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis in Patients With Type 2 Diabetes Mellitus on Treatment With Gastric Inhibitory Polypeptide / Glucagon Like Peptide-1 Analogue (Tirzpatide)

Sponsor: Dr Adnan Agha

Conditions Liver Fat Non-Alcoholic Fatty Liver Disease Non-alcoholic Steatohepatitis Type 2 Diabetes

Interventions GIP/GLP-1a

Updated 6 times since 2023 Last updated: Jan 10, 2024 Started: Oct 1, 2023 Primary completion: Oct 31, 2024 Completion: Feb 28, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Liver Fat and Non-Alcoholic Fatty Liver Disease and is currently ongoing. Dr Adnan Agha leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Sep 2025 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Apr 2023 — Feb 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr Adnan Agha

Data source: United Arab Emirates University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Al Ain City, United Arab Emirates